Corvus Pharmaceuticals, Inc. (CRVS) Tops Q3 EPS by 47c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q3 EPS of $0.32, $0.47 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Syensqo SA (SYENS:BB) PT Raised to EUR74 at Deutsche Bank
• AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion